Why to screen heart disease in diabetes

Atherosclerosis

Volumn 204, Issue 1, 2009, Pages 11-15

  Fadini, Gian Paolo ^a   de Kreutzenberg, Saula Vigili ^a   Tiengo, Antonio ^a   Avogaro, Angelo ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Coronary artery disease; Diabetes; Heart disease; Screening

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; SULFONYLUREA;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HEART DISEASE; HEART FAILURE; HIGH RISK POPULATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MASS SCREENING; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; PATIENT IDENTIFICATION; PRESCRIPTION; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK MANAGEMENT; SCREENING TEST; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

CORONARY ARTERY DISEASE; DIABETES COMPLICATIONS; EARLY DIAGNOSIS; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MASS SCREENING; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS;

EID: 67349094597     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.044     Document Type: Review

References (60)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
2. Wei M., Gaskill S.P., Haffner S.M., and Stern M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21 (1998) 1167-1172
3. Russell L.B., Valiyeva E., Roman S.H., et al. Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care 28 (2005) 1611-1617
4. Mulnier H.E., Seaman H.E., Raleigh V.S., et al. Mortality in people with type 2 diabetes in the UK. Diabetic Med 23 (2006) 516-521
5. Soedamah-Muthu S.S., Fuller J.H., Mulnier H.E., et al. High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29 (2006) 798-804
6. Booth G.L., Kapral M.K., Fung K., and Tu J.V. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368 (2006) 29-36
7. Napoli C., D'Armiento F.P., Mancini F.P., et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 100 (1997) 2680-2690
8. Napoli C., Glass C.K., Witztum J.L., et al. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) Study. Lancet 354 (1999) 1234-1241
9. Luscher T.F., Creager M.A., Beckman J.A., and Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part II. Circulation 108 (2003) 1655-1661
10. Creager M.A., Luscher T.F., Cosentino F., and Beckman J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy. Part I. Circulation 108 (2003) 1527-1532
11. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., and Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44 Suppl. 2 (2001) S14-S21
12. Geiss L.S. Diabetes in America. 2nd ed. (1995), NIH, Bethesda, MD
13. Norman P.E., Davis W.A., Bruce D.G., and Davis T.M. Peripheral arterial disease and risk of cardiac death in type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 29 (2006) 575-580
14. Sundstrom J., Riserus U., Byberg L., et al. Clinical value of the metabolic syndrome for long-term prediction of total and cardiovascular mortality: prospective, population-based cohort study. BMJ 332 (2006) 878-882
15. Kim W.Y., Astrup A.S., Stuber M., et al. Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathy. Circulation 115 (2007) 228-235
16. Soedamah-Muthu S.S., Chaturvedi N., Toeller M., et al. Risk factors for coronary heart disease in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study. Diabetes Care 27 (2004) 530-537
17. Wilkin T.J. The accelerator hypothesis: weight gain as the missing link between type i and type II diabetes. Diabetologia 44 (2001) 914-922
18. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
19. Schramm T.K., Gislason G.H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 117 (2008) 1945-1954
20. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004) 1047-1053
21. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
22. Ahmed J., Ward T.P., Bursell S.E., et al. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care 29 (2006) 2205-2209
23. Feldt-Rasmussen B., Borch-Johnsen K., Deckert T., Jensen G., and Jensen J.S. Microalbuminuria: an important diagnostic tool. J Diabetes Complicat 8 (1994) 137-145
24. Bax G., Fagherazzi C., Piarulli F., Nicolucci A., and Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI). A comparison with tests using the vibratory and thermal perception thresholds. Diabetes Care 19 (1996) 904-905
25. Faglia E., Caravaggi C., Marchetti R., et al. Screening for peripheral arterial disease by means of the ankle-brachial index in newly diagnosed type 2 diabetic patients. Diabetic Med 22 (2005) 1310-1314
26. Barett E., Ginsberg H., and Pauker S. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care (1998) 1551-1559
27. Bax J.J., Bonow R.O., Tschope D., Inzucchi S.E., and Barrett E. The potential of myocardial perfusion scintigraphy for risk stratification of asymptomatic patients with type 2 diabetes. J Am Coll Cardiol 48 (2006) 754-760
28. Scognamiglio R., Negut C., Ramondo A., Tiengo A., and Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol 47 (2006) 65-71
29. Wackers F., Young L., Inzucchi S., et al. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: The DIAD Study. Diabetes Care (2004) 1954-1961
30. Marfella R., D'Amico M., Di Filippo C., et al. Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1. Diabetologia 45 (2002) 1172-1181
31. Scognamiglio R., Casara D., and Avogaro A. Myocardial dysfunction and adrenergic innervation in patients with type 1 diabetes mellitus. Diabetes Nutr Metab 13 (2000) 346-349
32. Stern S., Behar S., Leor J., et al. Presenting symptoms, admission electrocardiogram, management, and prognosis in acute coronary syndromes: differences by age. Am J Geriatr Cardiol 13 (2004) 188-196
33. Gibbons R, Balady G, Bricker J, ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002, 1883-92.
34. Gottdiener J.S. Overview of stress echocardiography: uses, advantages, and limitations. Prog Cardiovasc Dis 43 (2001) 315-334
35. Salm L.P., Bax J.J., Jukema J.W., et al. Hemodynamic evaluation of saphenous vein coronary artery bypass grafts: relative merits of Doppler flow velocity and SPECT perfusion imaging. J Nucl Cardiol 12 (2005) 545-552
36. Bax J.J., Inzucchi S.E., Bonow R.O., et al. Cardiac imaging for risk stratification in diabetes. Diabetes Care 30 (2007) 1295-1304
37. Poornima I.G., Parikh P., and Shannon R.P. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98 (2006) 596-605
38. Scognamiglio R., Negut C., de Kreutzenberg S.V., Tiengo A., and Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 112 (2005) 179-184
39. Scognamiglio R., Negut C., de Kreutzenberg S.V., et al. Abnormal myocardial perfusion and contractile recruitment during exercise in type 1 diabetic patients. Clin Cardiol 28 (2005) 93-99
40. Bugiardini R., and Bairey Merz C.N. Angina with "normal" coronary arteries: a changing philosophy. JAMA 293 (2005) 477-484
41. Scognamiglio R., Avogaro A., Negut C., et al. Early myocardial dysfunction in the diabetic heart: current research and clinical applications. Am J Cardiol 93 (2004) 17A-20A
42. Nichols G.A., Hillier T.A., Erbey J.R., and Brown J.B. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 24 (2001) 1614-1619
43. Bell D.S. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 26 (2003) 2433-2441
44. Sipahi I., Tuzcu E.M., Schoenhagen P., et al. Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. Atherosclerosis 189 (2006) 229-235
45. Diamond G., Kaul S., and Shah P. Screen testing. Cardiovascular prevention in asymptomatic diabetic subjects. J Am Coll Cardiol 49 (2007) 1915-1917
46. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
47. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
48. Rodriguez-Granillo G.A., Agostoni P., Garcia-Garcia H.M., et al. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol 99 (2007) 5-10
49. Hong M.K., Lee C.W., Kim Y.H., et al. Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy. Am J Cardiol 98 (2006) 866-870
50. Russell M., Fleg J.L., Galloway W.J., et al. Examination of lower targets for low-density lipoprotein cholesterol and blood pressure in diabetes-The Stop Atherosclerosis in Native Diabetics Study (SANDS). Am Heart J 152 (2006) 867-875
51. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
52. Kiortsis D.N., Filippatos T.D., Mikhailidis D.P., Elisaf M.S., and Liberopoulos E.N. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 195 (2007) 7-16
53. Bax J.J., Young L.H., Frye R.L., et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care 30 (2007) 2729-2736
54. Waxman S., Ishibashi F., and Muller J.E. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 114 (2006) 2390-2411
55. Boden W., O'Rourke R., Teo K., et al. Optimal medical therapy with or without pci for stable coronary disease. N Engl J Med 356 (2007) 1503-1516
56. Barsness G.W., Gersh B.J., Brooks M.M., and Frye R.L. Rationale for the revascularization arm of the Bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Am J Cardiol 97 (2006) 31G-40G
57. Ramasubbu K., Estep J., White D.L., Deswal A., and Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008) 415-426
58. Scognamiglio R., Avogaro A., de Kreutzenberg S.V., et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 51 (2002) 808-812
59. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007) 1129-1136
60. European Medicines Agency, Galvus (vildagliptin), summary of product characteristics, www.emea.europa.eu/humandocs/PDFs/EPAR/galvus/H-771-PI-en.pdf.